Detailed company information
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 12, 2026
Earnings Transcript for 2026 - Q1Released: May 14, 2026
Earnings Transcript for 2025 - Q4Released: Mar 12, 2026
Earnings Transcript for 2025 - Q3Released: Nov 07, 2025
Earnings Transcript for 2025 - Q2Released: Aug 13, 2025
Earnings Transcript for 2025 - Q1Released: May 13, 2025
Earnings Transcript for 2024 - Q4Released: Mar 13, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q1Released: May 13, 2024
Earnings Transcript for 2023 - Q4Released: Mar 14, 2024
Earnings Transcript for 2023 - Q3Released: Nov 02, 2023
Earnings Transcript for 2023 - Q2Released: Aug 02, 2023
Earnings Transcript for 2023 - Q1Released: May 03, 2023
Earnings Transcript for 2022 - Q4Released: Feb 28, 2023
Earnings Transcript for 2022 - Q3Released: Nov 02, 2022
Earnings Transcript for 2022 - Q2Released: Aug 09, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Feb 23, 2022
Earnings Transcript for 2021 - Q3Released: Nov 04, 2021
Earnings Transcript for 2021 - Q2Released: Aug 04, 2021
Earnings Transcript for 2021 - Q1Released: May 05, 2021
Earnings Transcript for 2020 - Q4Released: Feb 28, 2021
Earnings Transcript for 2020 - Q3Released: Nov 04, 2020
Earnings Transcript for 2020 - Q2Released: Aug 06, 2020
IPSC Century Therapeutics, Inc.